Houston-based rBIO has invented a new process to churn out insulin at higher yields using custom-made bacteria.

Houston biotech startup is one step closer to releasing its marquee drug for the global insulin market, which is projected to break the $90 billion threshold by 2029.

rBIO’s lead biologic drug, R-biolin, aims to disrupt the $90bn insulin market through a biosimilar manufacturing technique that can be massively scaled to yield significant cost savings

The industrial biotechnology industry is one of the most promising new approaches to pollution prevention, resource conservation and cost reduction. With the industry expected to grow into a $4 trillion to $30 trillion sector, the Houston region is positioning itself as a leading synthetic bio industrial hub.   Houston is already